Search company, investor...

Founded Year



Loan | Alive

Total Raised


Last Raised

$250K | 4 yrs ago

About NeuroSky

NeuroSky is a company that specializes in health and wellness biometrics, operating in the wearable technology and mobile solutions sectors. The company offers EEG and ECG biosensors that provide insightful and easy-to-understand biometric data analysis, primarily used for monitoring and analyzing body and mind health. These technologies are primarily utilized in the consumer-facing wearable technology industry. It was founded in 2004 and is based in San Jose, California.

Headquarters Location

125 South Market Street

San Jose, California, 95113,

United States




Expert Collections containing NeuroSky

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

NeuroSky is included in 1 Expert Collection, including Smart Home & Consumer Electronics.


Smart Home & Consumer Electronics

1,234 items

This Collection includes companies developing smart home devices, wearables, home electronics, and other consumer electronics.

NeuroSky Patents

NeuroSky has filed 21 patents.

patents chart

Application Date

Grant Date


Related Topics




Sensors, Biosensors, Biotechnology, Gas sensors, Transducers


Application Date


Grant Date



Related Topics

Sensors, Biosensors, Biotechnology, Gas sensors, Transducers



Latest NeuroSky News

Brain Computer Interface Market is Projected to Gain $5,463.00 Million by 2030: Report by Allied Market Research

Nov 16, 2023

The leading companies of the market include Nihon Kohden Corporation, Advanced Brain Monitoring, Inc., Emotiv, Inc., Cadwell Laboratories Inc., Cortech Solutions, Inc., Guger Technologies, Integra LifeSciences, NeuroSky, Inc., Natus Medical Incorporated., and OpenBCI. These companies have employed different strategies such as mergers, collaborations, acquisitions, etc. to gain an advantage over their peers in the industry. Enquiry Before Buying: Key Industry Developments - On November 2023: Neurolutions, Inc., the leader in the use of non-invasive brain computer interface (BCI) technology for post-stroke therapy partnered with Kandu™ Health, a tech enabled health care services company that is changing the course of stroke recovery and post-acute care. Through this partnership the companies intends to accelerate access to breakthrough brain computer interface (BCI) and remote support for stroke rehabilitation. On October 2023: Butterfly Network, maker of a handheld, smartphone-connected ultrasound system partnered with Forest Neurotech, a tech-enabled research company building a device for stimulating and imaging the brain with ultrasound. Through this partnership the companies intends to develop a whole-brain neural interface utilizing Butterfly's Ultrasound-on-Chip technology. On October 2023: WiMi Hologram Cloud Inc., a leading global Hologram Augmented Reality ("AR") Technology provider launched a hybrid bios-signal-based brain-computer interface (HBS-BCI) that is rapidly gaining prominence. HBS-BCI technology is designed to improve classification accuracy, increase the number of commands, and shorten the time it takes for brain commands to be detected by integrating multiple biological signals. On January 2023: MicroCloud Hologram a Hologram Digital Twins Technology provider, launched its holographic BCI (Brain-Computer Interface) data acquisition system. Holographic technology can be used as an information feedback tool for BCI systems, providing more realistic, prosperous, and stimulating contextual feedback for a more immersive user experience. BCI can be used as an input device for the holographic system, providing more direct and faster input. On May 2022: Blackrock Neurotech acquired spatial computing software firm MindX to bolster its development of technologically advanced brain-computer interface products. BCI use in clinical applications is supported by user-friendly software that decodes neural activity and translates brain signals into digital commands. About Us: Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports Insights" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. We are in professional corporate relations with various companies, and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry. Tags

NeuroSky Frequently Asked Questions (FAQ)

  • When was NeuroSky founded?

    NeuroSky was founded in 2004.

  • Where is NeuroSky's headquarters?

    NeuroSky's headquarters is located at 125 South Market Street, San Jose.

  • What is NeuroSky's latest funding round?

    NeuroSky's latest funding round is Loan.

  • How much did NeuroSky raise?

    NeuroSky raised a total of $12.05M.

  • Who are the investors of NeuroSky?

    Investors of NeuroSky include Paycheck Protection Program, SoftBank, TUVC, Marubeni, Taiwan Global BioFund and 4 more.

  • Who are NeuroSky's competitors?

    Competitors of NeuroSky include Muse, NextMind, eSight, Bioness, Freer Logic and 7 more.


Compare NeuroSky to Competitors


Truthtek is a spin-out company from Manchester Metropolitan University with a suite of software for the analysis of non-verbal behaviour in video streams of structured interviews. The technology combines latest psychological research in non-verbal communication with leading image recognition and analysis software. Potential applications include lie detection, where the technology is non-invasive and has shown 85% accuracy in initial trials. MTF has provided initial seed capital to the company to enable it to develop its commercial and market-entry strategy.


DermIng, an independent private research Institute, carries out a series of clinical trials to measure the activity and tolerance of skin care treatments and products, and also developers the very latest non-invasive diagnostic bio-engineering systems.


Kjaya is a company that received a SBIR Phase I grant for a project entitled: Semi-Autonomous Adaptive Neural and Genetic Segmentation of Medical Images. Their Phase I project will implement a physician-assisted, real-time adaptive system for the segmentation of anatomical structures in 3D medical image data. Medical image segmentation seeks to change the representation of an anatomical structure, making it more easily analyzed. Because of the extreme variability of these structures in biological systems, current idiosyncratic manual methods currently in use are tedious, time consuming, and error prone. Image segmentation cannot in general be programmatically solved. The proposed system is a Neural Network (NN) based adaptation of the individual data using parallel Graphics Processing Units (GPUs) and coupled with a Genetic Algorithm (GA) based adaptation across GPU cores. The system will build a diagnostically useful segmentation of the anatomical feature within seconds from an area of interest outlined by a physician using a Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan. Fast growth in medical imaging overwhelms available diagnosticians. An intuitive and inexpensive system to quickly and accurately deliver diagnostic relevant segmentation of medical images offers tremendous commercial value. Currently, each scan requires approximately 50 minutes of manual preparation. The diagnosis and treatment of an estimated 20 percent of diseases benefit from medical imaging. Newer scanning technologies have increased in resolution, but such techniques have not made segmenting easier or faster. The proposed method will enable more diagnostics to be done with the quality controlled directly by physicians.

River Diagnostics

River Diagnostics is dedicated to the development of products for the healthcare and medical research marketplace based on the vast potential of non-invasive/non-destructive Raman spectroscopy. Today researchers in personal care, and dermatological research are using River Diagnostics' instruments to understand the metabolic processes in the skin, and other fundamental research questions.


CryoPen is a developer and manufacturer of state-of-the art medical devices and aesthetic treatment systems. CryoPen is committed to delivering the most effective, and profitable solutions available to healthcare providers, physicians of all specialties, and medical spas. The company's product portfolio aims to enable physicians to provide a higher quality of care and offer their patients a more diverse array of treatments while generating a substantial revenue stream for their practice. CryoPen's product set addresses a multitude of treatment applications such as laser hair removal, skin rejuvenation, cryosurgery, cellulite reduction, vascular lesions, pigmented lesions, acne, psoriasis, fine lines & wrinkles, scar and tattoo removal, photo facials, and skin tightening. With a dedication to the research and development of technologically advanced devices and equipment, every CryoPen product is designed to create a better patient experience, consistent clinical outcomes, and economic impact on the bottom line of their practice.

Endologix Logo

Endologix is a company focused on the development and manufacturing of minimally invasive treatments for aortic disorders, operating within the medical devices industry. The company's main offerings include a variety of endovascular stent grafts, which are used for the treatment of abdominal aortic aneurysms (AAA), a condition characterized by a weakening of the wall of the aorta that can lead to a balloon-like enlargement. Endologix primarily serves the healthcare sector, particularly in areas related to vascular disease and aortic disorders. It was founded in 1992 and is based in Irvine, California.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.